LINCOLNSHIRE, Illinois (May 12, 2010) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Rodman & Renshaw Annual Global Investment Conference which will be held from May 16-18 in London, UK.
Stephen M. Simes, BioSante’s president & CEO, will speak on Monday May 17, 2010 at 2:25 pm London time. He will provide a status report on BioSante’s portfolio of cancer vaccines in clinical development, as well as an update on LibiGel® (testosterone gel) in clinical development for the treatment of female sexual dysfunction. A live audio webcast of Mr. Simes’ remarks may be accessed at http ://www.wsw.com/webcast/rrshq17/bpax and a replay will be available at the same link.
About the Rodman & Renshaw and the Annual Global Investment Conference
More Than 1,000 Attendees & 175 Presenting Companies Expected to attend the conference. Rodman & Renshaw, LLC is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets and has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005 according to Sagient Research Systems.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to- severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development is a portfolio of cancer vaccines (GVAX), two of which have been granted orphan drug designation, currently in several Phase II clinical trials, at minimal cost to BioSante. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: http://www.biosantepharma.com
